Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
Abstract Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including sofosbuvir (SOF) plus different NS5A inhibitors, as we...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/kjm2.12315 |
| _version_ | 1818655556729044992 |
|---|---|
| author | Tzu‐Sheng Cheng Po‐Cheng Liang Chung‐Feng Huang Ming‐Lun Yeh Ching‐I Huang Zu‐Yau Lin Shinn‐Cherng Chen Jee‐Fu Huang Chia‐Yen Dai Ping‐Hsin Hsieh Wan‐Long Chuang Ming‐Lung Yu |
| author_facet | Tzu‐Sheng Cheng Po‐Cheng Liang Chung‐Feng Huang Ming‐Lun Yeh Ching‐I Huang Zu‐Yau Lin Shinn‐Cherng Chen Jee‐Fu Huang Chia‐Yen Dai Ping‐Hsin Hsieh Wan‐Long Chuang Ming‐Lung Yu |
| author_sort | Tzu‐Sheng Cheng |
| collection | DOAJ |
| description | Abstract Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including sofosbuvir (SOF) plus different NS5A inhibitors, as well as non‐SOF‐based DAAs, including glecaprevir/pibrentasvir (GLE/PIB), have been approved for treating CHC genotype‐2 (GT‐2) patients in Taiwan. However, there is limited real‐world effectiveness data regarding these different regimens. Thus, we aimed to evaluate the real‐world efficacy in CHC GT‐2 patients who underwent these DAA regimens. We retrospectively enrolled CHC GT‐2 patients who were treated with SOF‐based DAAs or GLE/PIB at a single medical center. A total of 704 enrolled patients were treated with either SOF + ribavirin (RBV), SOF/daclatasvir (DCV) ± RBV, SOF/ledipasvir (LDV) ± RBV, SOF/velpatasvir (VEL) ± RBV, or with GLE/PIB. The overall sustained virological response (SVR) rate was 97.9%. The SVR rate was significantly lower in the SOF + RBV group (95.6%) than in the non‐SOF + RBV (98.9%) group, especially compared to the SOF/DCV (100%) and GLE/PIB groups (99.5%). Among patients treated with SOF + RBV, cirrhotic patients had significantly lower SVR rates than noncirrhotic patients (89.4% vs 98.2%). Multivariate analysis showed that patients with a younger age, hepatitis B virus coinfection, baseline cirrhosis, or those who received SOF + RBV were less likely to achieve SVR. In conclusion, for CHC GT‐2 patients, SOF in combination with DCV, LDV, or VEL, as well as GLE/PIB, achieved similar high efficacies, regardless of cirrhosis, treatment experience, or chronic kidney disease status. Therefore, the use of DAA therapy to eradicate HCV should not be delayed in these populations. |
| first_indexed | 2024-12-17T03:11:34Z |
| format | Article |
| id | doaj.art-d04f3744ee2a453faa48c543e41a5205 |
| institution | Directory Open Access Journal |
| issn | 1607-551X 2410-8650 |
| language | English |
| last_indexed | 2024-12-17T03:11:34Z |
| publishDate | 2021-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Kaohsiung Journal of Medical Sciences |
| spelling | doaj.art-d04f3744ee2a453faa48c543e41a52052022-12-21T22:05:50ZengWileyKaohsiung Journal of Medical Sciences1607-551X2410-86502021-04-0137433434510.1002/kjm2.12315Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatmentTzu‐Sheng Cheng0Po‐Cheng Liang1Chung‐Feng Huang2Ming‐Lun Yeh3Ching‐I Huang4Zu‐Yau Lin5Shinn‐Cherng Chen6Jee‐Fu Huang7Chia‐Yen Dai8Ping‐Hsin Hsieh9Wan‐Long Chuang10Ming‐Lung Yu11Hepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanDepartment of Internal Medicine Chi Mei Hospital, Liouying Tainan TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung TaiwanAbstract Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including sofosbuvir (SOF) plus different NS5A inhibitors, as well as non‐SOF‐based DAAs, including glecaprevir/pibrentasvir (GLE/PIB), have been approved for treating CHC genotype‐2 (GT‐2) patients in Taiwan. However, there is limited real‐world effectiveness data regarding these different regimens. Thus, we aimed to evaluate the real‐world efficacy in CHC GT‐2 patients who underwent these DAA regimens. We retrospectively enrolled CHC GT‐2 patients who were treated with SOF‐based DAAs or GLE/PIB at a single medical center. A total of 704 enrolled patients were treated with either SOF + ribavirin (RBV), SOF/daclatasvir (DCV) ± RBV, SOF/ledipasvir (LDV) ± RBV, SOF/velpatasvir (VEL) ± RBV, or with GLE/PIB. The overall sustained virological response (SVR) rate was 97.9%. The SVR rate was significantly lower in the SOF + RBV group (95.6%) than in the non‐SOF + RBV (98.9%) group, especially compared to the SOF/DCV (100%) and GLE/PIB groups (99.5%). Among patients treated with SOF + RBV, cirrhotic patients had significantly lower SVR rates than noncirrhotic patients (89.4% vs 98.2%). Multivariate analysis showed that patients with a younger age, hepatitis B virus coinfection, baseline cirrhosis, or those who received SOF + RBV were less likely to achieve SVR. In conclusion, for CHC GT‐2 patients, SOF in combination with DCV, LDV, or VEL, as well as GLE/PIB, achieved similar high efficacies, regardless of cirrhosis, treatment experience, or chronic kidney disease status. Therefore, the use of DAA therapy to eradicate HCV should not be delayed in these populations.https://doi.org/10.1002/kjm2.12315chronic hepatitis CDAAsgenotype 2HCVTaiwan |
| spellingShingle | Tzu‐Sheng Cheng Po‐Cheng Liang Chung‐Feng Huang Ming‐Lun Yeh Ching‐I Huang Zu‐Yau Lin Shinn‐Cherng Chen Jee‐Fu Huang Chia‐Yen Dai Ping‐Hsin Hsieh Wan‐Long Chuang Ming‐Lung Yu Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment Kaohsiung Journal of Medical Sciences chronic hepatitis C DAAs genotype 2 HCV Taiwan |
| title | Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment |
| title_full | Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment |
| title_fullStr | Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment |
| title_full_unstemmed | Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment |
| title_short | Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment |
| title_sort | real world effectiveness of direct acting antiviral agents for chronic hepatitis c patients with genotype 2 infection after completed treatment |
| topic | chronic hepatitis C DAAs genotype 2 HCV Taiwan |
| url | https://doi.org/10.1002/kjm2.12315 |
| work_keys_str_mv | AT tzushengcheng realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT pochengliang realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT chungfenghuang realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT minglunyeh realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT chingihuang realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT zuyaulin realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT shinncherngchen realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT jeefuhuang realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT chiayendai realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT pinghsinhsieh realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT wanlongchuang realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment AT minglungyu realworldeffectivenessofdirectactingantiviralagentsforchronichepatitiscpatientswithgenotype2infectionaftercompletedtreatment |